IND-SWIFT LABORATORIES LTD.

Ind-Swift Laboratories Ltd has announced the closure of its trading window for dealing in the company's securities. This closure is effective from July 1, 2026, and will remain in effect until 48 hours after the declaration of the Un-audited Standalone & Consolidated Financial Results for the quarter ended June 30, 2026. The restriction applies to promoters, directors, KMPs, designated persons, connected persons, insiders, and their immediate relatives, in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015.

Mr. Prabhat Khurana has resigned as an Independent Director of Ind-Swift Laboratories Ltd. due to personal and professional commitments. His resignation is effective from the close of business hours on June 22, 2026. The Board of Directors has acknowledged his contributions. Mr. Khurana confirmed there are no other material reasons for his resignation beyond those stated.

Ind-Swift Laboratories Ltd announced the re-appointment of Sh. Rajinder Kumar Gupta as Non-Executive Independent Director for a second term of five years, commencing June 23, 2026, subject to shareholder approval. The Board also approved the reconstitution of key committees, including the Audit Committee, Stakeholders Relationship Committee, and Risk Management Committee. Sh. Gupta, a retired Additional Commissioner of Income Tax with extensive experience in tax, administration, and legal matters, is not related to any other director of the company. The changes are effective immediately, with the shareholder approval to be obtained within three months.

Ind-Swift Laboratories Limited confirmed no deviation or variation in the use of funds raised through its Preferential Issue of Convertible Warrants for the quarter ended March 31, 2026. The original issue size was ₹314.60 Crores, but the actual realizable proceeds have been revised to ₹255.61 Crores. This adjustment follows the forfeiture of ₹19.66 Crores from SARAL INCORPORATED VCC SUB FUND 1 due to unexercised warrants and an additional ₹58.99 Crores becoming non-receivable from the same allottee. The company utilized ₹232.02 Crores as of March 31, 2026, towards business expansion, investment in subsidiaries, working capital, and general corporate purposes. The Nil Statement of Deviation was duly reviewed by the Audit Committee.

Ind-Swift Laboratories Ltd.'s Board of Directors, at its meeting on May 28, 2026, approved the audited financial results for the fourth quarter and the full financial year ended March 31, 2026. These results, presented on both standalone and consolidated bases, include the Statement of Profit & Loss, Statement of Assets & Liabilities, and Statement of Cash Flow. The financial statements were reviewed by the Audit Committee and audited by M/s. Rattan Kaur & Associates. Additionally, the Board re-appointed M/s. V. Kumar & Associates as Cost Auditors for the financial year 2026-27.

The Board of Directors of 532305, at its meeting on May 28, 2026, approved the audited financial results for the fourth quarter and financial year ended March 31, 2026. These results, covering both standalone and consolidated bases, include the Statement of Profit & Loss, Statement of Assets & Liabilities, and Statement of Cash Flow. The financial statements were reviewed by the Audit Committee and audited by M/s. Rattan Kaur & Associates, Chartered Accountants, who issued an unmodified opinion. Additionally, the Board re-appointed M/s. V. Kumar & Associates as Cost Auditors for the financial year 2026-27.

Ind-Swift Laboratories Ltd has scheduled a Board of Directors meeting on May 28, 2026, to consider, approve, and take on record the Standalone and Consolidated Audited Financial Results of the Company for the quarter and financial year ended March 31, 2026. The company had already informed the stock exchanges about the closure of the Trading Window on March 31, 2026.

Ind-Swift Laboratories Ltd has released the Monitoring Agency Report by CARE Ratings Limited for the quarter ended March 31, 2026, regarding the utilization of proceeds from a preferential issue of ₹314.60 crore. The report indicates no deviations from the stated objectives of the issue. The Audit Committee and the Board have reviewed and taken the report on record, as per SEBI regulations.

HCP Investments disposed of 6,503,423 equity shares of Ind-Swift Laboratories Limited, representing 7.5% of the total paid-up share capital, between April 13 and April 16, 2026. Before the disposal, HCP Investments held 7,500,000 shares (8.649%). After the sale, the holding decreased to 996,577 shares (1.149%). The disposals were made through open market transactions.

HCP Investments has disclosed the disposal of 6,503,423 equity shares of Ind-Swift Laboratories Ltd., representing 7.5% of the target company's total paid-up share capital. This transaction, conducted via open market from April 13 to April 16, 2026, has reduced HCP Investments' holding in Ind-Swift Laboratories from 8.649% (7,500,000 shares) to 1.149% (996,577 shares). The disclosure was made under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.